Navigation Links
Infection biology: The elusive third factor
Date:6/22/2012

Researchers from Ludwig-Maximilians-Universitt (LMU) in Munich have identified an enzyme that is involved in a modification pathway that is essential for bacterial pathogenicity. Because it shows no similarity to other known proteins, it may be an ideal target for development of novel antimicrobial drugs.

Studies on a number of pathogenic bacteria have shown that these strains become pathogenic only when an enzyme called elongation factor P (EF-P) is chemically modified on a conserved lysine residue. EF-P is a universally conserved translation factor, which is involved in protein synthesis. Two enzymes are known to be involved in modifying the conserved lysine of EF-P, however these enzymes cannot fully account for the pattern of modification seen on EF-P in living cells.

The mystery molecule

Thus, at least one other protein must be involved in the modification process however to date it has proved to be particularly elusive. Now a research team led by LMU biochemist Daniel Wilson, who is also affiliated with the Center for Integrated Protein Science Munich (CIPSM), a Cluster of Excellence at LMU, has succeeded in identifying the mystery protein as the enzyme YfcM and showing that it displays hydroxylase activity. Strikingly, YfcM shows no sequence similarity to any other known protein and therefore may have a unique structure.

This is not the only reason why discovery of YfcM will arouse great interest. "YfcM may turn out to be an ideal target for the development of new - and urgently needed antibiotics, however more insight will be needed to ascertain the role of the YfcM mediated hydroxylation of EF-P," says Wilson.


'/>"/>
Contact: Luise Dirscherl
dirscherl@lmu.de
49-892-180-2706
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Page: 1

Related biology news :

1. Childhood virus infection linked to prolonged seizures with fever
2. How alert hospital employees improved hospitals MSRA infection rate
3. New data suggests HIV superinfection rate comparable to initial HIV infection
4. Vitamin D supplements may protect against viral infections during the winter
5. Salmonella infection, but not as we know it
6. Bartonella infection associated with rheumatoid illnesses in humans
7. Women & Infants participating in study of treatment of common viral infection in pregnancy
8. To drive infections, a hijacking virus mimics a cells signaling system
9. BPA could affect reproductive capabilities, cause infection of the uterus
10. Queens scientists seek vaccine for Pseudomonas infection
11. New screening technique yields elusive compounds to block immune-regulating enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... , ... August 02, 2018 , ... ... solutions to pharmaceutical and biotech companies, today announced that Mark Jara, principal of ... inspiring people in the life sciences industry. Individuals named to PharmaVOICE 100 are ...
(Date:8/1/2018)... TUCSON, Ariz. & GILBERT, Ariz. (PRWEB) , ... ... ... Ever James A. May Father of Stevia Awards at Global Conference , Awards ... Michael P. May, Ph.D., president of Wisdom National Brands, presented prestigious stevia awards ...
(Date:7/31/2018)... ... 2018 , ... ACEA Biosciences, is a privately owned biotechnology company which develops ... xCELLigence RTCA S16, which the ideal entry level model for exploratory studies in cell ... placed in any standard CO2 tissue culture incubator. The user friendly RTCA software ...
Breaking Biology News(10 mins):
(Date:8/17/2018)... , ... August 16, 2018 , ... ... (CRO) is pleased to announce the expansion of their team. Dr. Dawn Dufield, ... to launch an innovative large molecule LC-MS/MS group that will specialize in developing ...
(Date:8/14/2018)... ... August 14, 2018 , ... Buprenorphine (BUP) is a ... is often prescribed as a sublingual co-formulation with the opioid antagonist naloxone (NXO) ... will learn from a review of the pharmacokinetics of BUP, NBP, and NXO ...
(Date:8/9/2018)... ... August 08, 2018 , ... ActX ... and is continually updated by a talented scientific team that includes geneticists, PharmD’s, ... , 1. Information on the medical impact of a patient’s genetic variants ...
(Date:8/9/2018)... ... August 09, 2018 , ... Rockland Immunochemicals, ... Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article ... published online on August 9, 2018 and will be printed in the September ...
Breaking Biology Technology: